GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).

Transcription:

¿Hay alguna terapia de inducción preferida?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding the new antibodies for multiple myeloma (MM) therapy (¿Cuáles son los anticuerpos nuevos para la terapia del mieloma múltiple (MM)?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple). 

We would like to thank the following company for their support of this program:

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).

We would like to thank the following company for their support of this program:

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there is a best maintenance therapy (¿Existe una terapia de mantenimiento mejor sobre las demás?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).

We would like to thank the following company for their support of this program:

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias mieloproliferativas (NMP) en la leucemia mieloide aguda (LMA)?).

GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?).  Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Acute Myeloid Leukemia & Myelodysplastic Syndrome, (Leucemia mieloide aguda y síndrome mielodisplásico).

We would like to thank the following company for their support of this program:

GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad).  Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Acute Myeloid Leukemia & Myelodysplastic Syndrome (Leucemia mieloide aguda y síndrome mielodisplásico)

We would like to thank the following company for their support of this program:

GRACE sat down with Dr.

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of surveillance imaging in indolent lymphomas and chronic lymphocytic leukemia (CLL) (¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?).  Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin).

GRACE sat down with Dr. Marco Ruiz to discuss information regarding all diffuse large B-cell lymphoma (DLBCL) and are they made equally ("¿Todos los linfomas difusos de linfocitos B (DLBCL) están hechos iguales?"). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin).

We would like to thank the following company for their support of this program: